哌柏西利辅助治疗早期乳腺癌:PALLAS试验结果(ABCSG-42/AFT-05/BIG-14-03)
PALLAS是一项前瞻性随机III期试验,纳入5796例激素受体阳性、HER2阴性早期乳腺癌患者,随机接受2年哌柏西利(125mg口服,每日一次,28天周期第1-21天)联合辅助内分泌治疗或单用辅助内分泌治疗。
要点
- 在激素受体阳性早期乳腺癌中,辅助内分泌治疗加用2年哌柏西利未改善iDFS。
- 次要终点及亚组分析均未显示显著差异,无新的安全性信号。
核心结论
- 在PALLAS试验最终分析中,早期激素受体阳性乳腺癌患者在标准内分泌治疗基础上加用辅助哌柏西利,相比单用内分泌治疗未改善结局。
研究设计与样本
- 前瞻性、随机、III期PALLAS试验,全球21个国家406个中心在3年内入组5796例患者,意向治疗人群5761例。
- 患者为激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌,随机接受2年哌柏西利(125 mg口服,每日一次,28天周期第1-21天)联合辅助内分泌治疗或单用辅助内分泌治疗(至少5年)。
- 主要终点为浸润性疾病无生存(iDFS);次要终点为浸润性乳腺癌无生存、无远处复发生存、无局部区域癌生存和总生存。
主要发现
- 中位随访31个月,哌柏西利联合内分泌治疗组2884例中253例(8.8%)发生iDFS事件,单用内分泌治疗组2877例中263例(9.1%)发生iDFS事件。
- 次要时间-事件终点均未观察到显著差异,亚组分析未显示任何亚组间差异。
- 本试验中哌柏西利未出现新的安全性信号。
关键数值与推荐
- 哌柏西利用法:125 mg口服,每日一次,28天周期第1-21天,共2年。
- 辅助内分泌治疗至少5年。
- 主要终点iDFS事件:哌柏西利联合组253/2884(8.8%) vs 单用内分泌组263/2877(9.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer-free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.
引用
- Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021. PMID: 34874182. doi:10.1200/JCO.21.02554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。